5 recruiting, 4 completed, 3 terminated, 3 unknown. 11 Phase 1, 9 Phase 2, 1 Early Phase 1.
Follow TIL: new trials by email Literature Review of TIL trials Research Report on TIL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma TILT-123, TIL, Cyclophosphamide - Metastatic Melanoma | Phase 1 | Active not recruiting | TILT Biotherapeutics Ltd. | 9 | 2025-06-25 | 2026-03-05 |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. Lifileucel - Endometrial Cancer | Phase 2 | Recruiting | Iovance Biotherapeutics, Inc. | 60 | 2024-10-29 | 2025-10-30 |
| Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide - Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2023-03-10 | 2026-09-16 |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers E7 TCR-T cells, Aldesleukin - Cervical Cancer, Throat Cancer | Phase 2 | Recruiting | Christian Hinrichs | 20 | 2023-03-07 | 2026-10-28 |
| KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer KK-LC-1 TCR-T cells, Aldesleukin - Gastric Cancer, Breast Cancer | Phase 1 | Recruiting | Christian Hinrichs | 30 | 2022-09-26 | 2026-10-28 |
| OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial) cyclophosphamide, fludarabine, IL-2 (Proleukin) - Ovarian Cancer Metastatic | Phase 1 / Phase 2 | Withdrawn | Immetacyte Ltd | 2020-07-01 | 2020-12-16 | |
| Immunotherapy for the Treatment of Advanced Solid Tumor TIL, Aldesleukin, Cyclophosphamide - Recurrence Tumor, Metastatic Cancer | Phase 1 / Phase 2 | Unknown | Tongji Hospital | 40 | 2020-04-28 | 2024-08-13 |
| Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma TIL, Interleukin-2, Fludarabine - Sarcoma | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 9 | 2019-09-27 | 2026-02-20 |
| Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors TIL, Cyclophosphamide, Fludarabine - Solid Tumor, Adult | Phase 1 | Terminated | Centre Hospitalier Universitaire Vaudois | 6 | 2019-09-01 | 2021-03-18 |
| TIL-ACT After NMA Chemo with IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL) TIL, Cyclophosphamide, Fludarabine - Metastatic Melanoma | Phase 1 | Completed | Centre Hospitalier Universitaire Vaudois | 18 | 2018-02-21 | 2025-02-11 |
| Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide - Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 20 | 2017-10-11 | 2023-07-24 |
| Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients Fludarabine, Cyclophosphamide, TIL - Malignant Melanoma Stage IV | Phase 2 | Unknown | Sheba Medical Center | 30 | 2017-06-05 | 2023-01-26 |
| Adoptive Cell Therapy of Autologous TIL and PD1-TIL Cells for Patients With Glioblastoma Multiforme TIL, PD1-TIL - Glioblastoma Multiforme | Early Phase 1 | Unknown | Huashan Hospital | 40 | 2017-01-01 | 2021-08-25 |
| TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment Cyclophosphamide, Fludarabine, Tumour Infiltrating Lymphocytes - Metastatic Melanoma | Phase 2 | Terminated | The Christie NHS Foundation Trust | 2 | 2014-03-01 | 2023-04-20 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers Fludarabine, Cyclophosphamide, Young TIL - Cervical Cancer, Oropharyngeal Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 29 | 2012-04-13 | 2018-03-07 |
| Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes - Metastatic Melanoma, Skin Cancer | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2011-05-01 | 2015-01-27 |
Melanoma (5) · Uterine Cervical Neoplasms (4) · Anus Neoplasms (3) · Oropharyngeal Neoplasms (3) · Penile Neoplasms (3) · Vaginal Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Neoplasm Metastasis (2) · Recurrence (2) · Vulvar Neoplasms (2) · Adenocarcinoma (1) · Breast Neoplasms (1) · Carcinoma, Adenosquamous (1) · Carcinoma, Squamous Cell (1)
Christian Hinrichs (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Centre Hospitalier Universitaire Vaudois (2) · National Cancer Institute (NCI) (2) · Huashan Hospital (1) · Immetacyte Ltd (1) · Iovance Biotherapeutics, Inc. (1) · Sheba Medical Center (1) · TILT Biotherapeutics Ltd. (1) · The Christie NHS Foundation Trust (1) · Tongji Hospital (1)
United States (9) · China (2) · Switzerland (2) · United Kingdom (2) · Denmark (1) · Israel (1)
Christian S Hinrichs, MD (3) · George Coukos, MD, PhD (2) · Steven A Rosenberg, M.D. (2) · Ben Creelan, M.D. (1) · Ben Creelan, MD, MS (1) · Fiona Thistlethwaite, PhD, MRCP (1) · Hui Wang, MD (1) · Inge Marie Svane (1) · John Mullinax, MD (1) · Paul Lorigan, MD (1) · Robert E Hawkins, MD (1)
PMID 34385708, PMID 25823737, PMID 30714987, PMID 33990415, PMID 38490980
2019 (1), K08CA252642 (1), U01CA287904 (1)